nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP2E1—liver cancer	0.48	1	CbGaD
Ondansetron—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0619	0.199	CbGbCtD
Ondansetron—CYP3A7—Sorafenib—liver cancer	0.0619	0.199	CbGbCtD
Ondansetron—CYP3A5—Sorafenib—liver cancer	0.0464	0.149	CbGbCtD
Ondansetron—CYP1A2—Sorafenib—liver cancer	0.0346	0.111	CbGbCtD
Ondansetron—CYP2C9—Sorafenib—liver cancer	0.0311	0.1	CbGbCtD
Ondansetron—CYP2D6—Sorafenib—liver cancer	0.0285	0.0916	CbGbCtD
Ondansetron—CYP3A4—Sorafenib—liver cancer	0.0181	0.0583	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—liver cancer	0.0173	0.0556	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—liver cancer	0.011	0.0353	CbGbCtD
Ondansetron—Alosetron—CYP2E1—liver cancer	0.00556	1	CrCbGaD
Ondansetron—Electrocardiogram ST segment depression—Epirubicin—liver cancer	0.00279	0.0276	CcSEcCtD
Ondansetron—Electrocardiogram ST segment depression—Doxorubicin—liver cancer	0.00258	0.0256	CcSEcCtD
Ondansetron—Myocardial ischaemia—Sorafenib—liver cancer	0.00213	0.0211	CcSEcCtD
Ondansetron—Neoplasm malignant—Sorafenib—liver cancer	0.00201	0.0199	CcSEcCtD
Ondansetron—Warmth—Epirubicin—liver cancer	0.00199	0.0197	CcSEcCtD
Ondansetron—Warmth—Doxorubicin—liver cancer	0.00184	0.0183	CcSEcCtD
Ondansetron—Hepatic failure—Sorafenib—liver cancer	0.00138	0.0137	CcSEcCtD
Ondansetron—Anorectal discomfort—Epirubicin—liver cancer	0.00116	0.0115	CcSEcCtD
Ondansetron—Blindness—Epirubicin—liver cancer	0.00114	0.0113	CcSEcCtD
Ondansetron—Local reaction—Epirubicin—liver cancer	0.00114	0.0113	CcSEcCtD
Ondansetron—Hypokalaemia—Sorafenib—liver cancer	0.00113	0.0112	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.00112	0.0111	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00112	0.0111	CcSEcCtD
Ondansetron—Anorectal discomfort—Doxorubicin—liver cancer	0.00107	0.0106	CcSEcCtD
Ondansetron—Local reaction—Doxorubicin—liver cancer	0.00106	0.0105	CcSEcCtD
Ondansetron—Blindness—Doxorubicin—liver cancer	0.00106	0.0105	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00095	0.00941	CcSEcCtD
Ondansetron—Acute coronary syndrome—Sorafenib—liver cancer	0.000945	0.00936	CcSEcCtD
Ondansetron—Myocardial infarction—Sorafenib—liver cancer	0.000939	0.00931	CcSEcCtD
Ondansetron—Redness—Epirubicin—liver cancer	0.000938	0.00929	CcSEcCtD
Ondansetron—Hepatobiliary disease—Sorafenib—liver cancer	0.000906	0.00898	CcSEcCtD
Ondansetron—Redness—Doxorubicin—liver cancer	0.000868	0.0086	CcSEcCtD
Ondansetron—Haemoglobin—Sorafenib—liver cancer	0.000865	0.00857	CcSEcCtD
Ondansetron—Haemorrhage—Sorafenib—liver cancer	0.00086	0.00852	CcSEcCtD
Ondansetron—Erythema multiforme—Sorafenib—liver cancer	0.000813	0.00806	CcSEcCtD
Ondansetron—Feeling hot—Epirubicin—liver cancer	0.000807	0.00799	CcSEcCtD
Ondansetron—Cardiac disorder—Sorafenib—liver cancer	0.000798	0.00791	CcSEcCtD
Ondansetron—Flushing—Sorafenib—liver cancer	0.000798	0.00791	CcSEcCtD
Ondansetron—Angiopathy—Sorafenib—liver cancer	0.000781	0.00773	CcSEcCtD
Ondansetron—Immune system disorder—Sorafenib—liver cancer	0.000777	0.0077	CcSEcCtD
Ondansetron—Injection site pain—Epirubicin—liver cancer	0.000775	0.00768	CcSEcCtD
Ondansetron—Mediastinal disorder—Sorafenib—liver cancer	0.000775	0.00768	CcSEcCtD
Ondansetron—Arrhythmia—Sorafenib—liver cancer	0.000769	0.00761	CcSEcCtD
Ondansetron—Erythema—Sorafenib—liver cancer	0.000749	0.00742	CcSEcCtD
Ondansetron—Feeling hot—Doxorubicin—liver cancer	0.000746	0.00739	CcSEcCtD
Ondansetron—Neoplasm malignant—Epirubicin—liver cancer	0.000741	0.00735	CcSEcCtD
Ondansetron—Cardiovascular disorder—Epirubicin—liver cancer	0.000721	0.00714	CcSEcCtD
Ondansetron—Injection site pain—Doxorubicin—liver cancer	0.000718	0.00711	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Epirubicin—liver cancer	0.000701	0.00694	CcSEcCtD
Ondansetron—Neoplasm malignant—Doxorubicin—liver cancer	0.000686	0.0068	CcSEcCtD
Ondansetron—Angioedema—Sorafenib—liver cancer	0.000684	0.00678	CcSEcCtD
Ondansetron—Dyskinesia—Epirubicin—liver cancer	0.000674	0.00667	CcSEcCtD
Ondansetron—Syncope—Sorafenib—liver cancer	0.000672	0.00665	CcSEcCtD
Ondansetron—Cardiovascular disorder—Doxorubicin—liver cancer	0.000667	0.00661	CcSEcCtD
Ondansetron—Loss of consciousness—Sorafenib—liver cancer	0.000658	0.00652	CcSEcCtD
Ondansetron—Cough—Sorafenib—liver cancer	0.000654	0.00647	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Doxorubicin—liver cancer	0.000649	0.00643	CcSEcCtD
Ondansetron—Musculoskeletal pain—Epirubicin—liver cancer	0.000641	0.00635	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000633	0.00627	CcSEcCtD
Ondansetron—Hiccups—Epirubicin—liver cancer	0.000633	0.00627	CcSEcCtD
Ondansetron—Hepatocellular injury—Epirubicin—liver cancer	0.000633	0.00627	CcSEcCtD
Ondansetron—Injection site reaction—Epirubicin—liver cancer	0.000629	0.00624	CcSEcCtD
Ondansetron—Dry mouth—Sorafenib—liver cancer	0.000624	0.00618	CcSEcCtD
Ondansetron—Dyskinesia—Doxorubicin—liver cancer	0.000623	0.00618	CcSEcCtD
Ondansetron—Anaphylactic shock—Sorafenib—liver cancer	0.000611	0.00606	CcSEcCtD
Ondansetron—Shock—Sorafenib—liver cancer	0.000601	0.00596	CcSEcCtD
Ondansetron—Nervous system disorder—Sorafenib—liver cancer	0.000599	0.00594	CcSEcCtD
Ondansetron—Skin disorder—Sorafenib—liver cancer	0.000594	0.00588	CcSEcCtD
Ondansetron—Musculoskeletal pain—Doxorubicin—liver cancer	0.000593	0.00587	CcSEcCtD
Ondansetron—Hepatocellular injury—Doxorubicin—liver cancer	0.000586	0.0058	CcSEcCtD
Ondansetron—Hiccups—Doxorubicin—liver cancer	0.000586	0.0058	CcSEcCtD
Ondansetron—Injection site reaction—Doxorubicin—liver cancer	0.000582	0.00577	CcSEcCtD
Ondansetron—Dyspnoea—Sorafenib—liver cancer	0.000545	0.0054	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Sorafenib—liver cancer	0.000528	0.00523	CcSEcCtD
Ondansetron—Fatigue—Sorafenib—liver cancer	0.000527	0.00522	CcSEcCtD
Ondansetron—Constipation—Sorafenib—liver cancer	0.000523	0.00518	CcSEcCtD
Ondansetron—Pain—Sorafenib—liver cancer	0.000523	0.00518	CcSEcCtD
Ondansetron—Hepatic failure—Epirubicin—liver cancer	0.000511	0.00507	CcSEcCtD
Ondansetron—Gastrointestinal pain—Sorafenib—liver cancer	0.0005	0.00495	CcSEcCtD
Ondansetron—Urticaria—Sorafenib—liver cancer	0.000486	0.00481	CcSEcCtD
Ondansetron—Abdominal pain—Sorafenib—liver cancer	0.000483	0.00479	CcSEcCtD
Ondansetron—Body temperature increased—Sorafenib—liver cancer	0.000483	0.00479	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Epirubicin—liver cancer	0.000475	0.0047	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—liver cancer	0.000473	0.00469	CcSEcCtD
Ondansetron—Hypersensitivity—Sorafenib—liver cancer	0.00045	0.00446	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000439	0.00435	CcSEcCtD
Ondansetron—Asthenia—Sorafenib—liver cancer	0.000439	0.00434	CcSEcCtD
Ondansetron—Pruritus—Sorafenib—liver cancer	0.000432	0.00428	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—liver cancer	0.000424	0.0042	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—liver cancer	0.000418	0.00414	CcSEcCtD
Ondansetron—Diarrhoea—Sorafenib—liver cancer	0.000418	0.00414	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000414	0.0041	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000414	0.0041	CcSEcCtD
Ondansetron—Dizziness—Sorafenib—liver cancer	0.000404	0.004	CcSEcCtD
Ondansetron—Asthma—Epirubicin—liver cancer	0.000397	0.00394	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—liver cancer	0.000393	0.00389	CcSEcCtD
Ondansetron—Vomiting—Sorafenib—liver cancer	0.000389	0.00385	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—liver cancer	0.000387	0.00383	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—liver cancer	0.000387	0.00383	CcSEcCtD
Ondansetron—Rash—Sorafenib—liver cancer	0.000385	0.00382	CcSEcCtD
Ondansetron—Dermatitis—Sorafenib—liver cancer	0.000385	0.00381	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000383	0.00379	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000383	0.00379	CcSEcCtD
Ondansetron—Headache—Sorafenib—liver cancer	0.000383	0.00379	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—liver cancer	0.000371	0.00368	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—liver cancer	0.000368	0.00364	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—liver cancer	0.000358	0.00355	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—liver cancer	0.000354	0.00351	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000351	0.00348	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—liver cancer	0.000344	0.00341	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—liver cancer	0.000344	0.0034	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—liver cancer	0.000335	0.00332	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—liver cancer	0.000328	0.00325	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000325	0.00322	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—liver cancer	0.000324	0.00321	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—liver cancer	0.00032	0.00317	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—liver cancer	0.000319	0.00316	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—liver cancer	0.000318	0.00315	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—liver cancer	0.00031	0.00307	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—liver cancer	0.000306	0.00304	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—liver cancer	0.000301	0.00298	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—liver cancer	0.000299	0.00297	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—liver cancer	0.000297	0.00294	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—liver cancer	0.000296	0.00293	CcSEcCtD
Ondansetron—Flushing—Epirubicin—liver cancer	0.000295	0.00292	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—liver cancer	0.000295	0.00292	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—liver cancer	0.000294	0.00291	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—liver cancer	0.000288	0.00286	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—liver cancer	0.000287	0.00285	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—liver cancer	0.000287	0.00284	CcSEcCtD
Ondansetron—Chills—Epirubicin—liver cancer	0.000285	0.00283	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—liver cancer	0.000284	0.00281	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—liver cancer	0.000284	0.00281	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—liver cancer	0.000278	0.00276	CcSEcCtD
Ondansetron—Erythema—Epirubicin—liver cancer	0.000277	0.00274	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—liver cancer	0.000275	0.00272	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—liver cancer	0.000273	0.0027	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—liver cancer	0.000273	0.0027	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—liver cancer	0.000273	0.0027	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—liver cancer	0.000267	0.00264	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—liver cancer	0.000266	0.00263	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—liver cancer	0.000265	0.00263	CcSEcCtD
Ondansetron—Chills—Doxorubicin—liver cancer	0.000264	0.00262	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—liver cancer	0.000263	0.0026	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—liver cancer	0.000261	0.00258	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—liver cancer	0.000257	0.00254	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—liver cancer	0.000256	0.00254	CcSEcCtD
Ondansetron—Agitation—Epirubicin—liver cancer	0.000254	0.00252	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—liver cancer	0.000252	0.0025	CcSEcCtD
Ondansetron—Malaise—Epirubicin—liver cancer	0.00025	0.00247	CcSEcCtD
Ondansetron—Syncope—Epirubicin—liver cancer	0.000248	0.00246	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—liver cancer	0.000245	0.00242	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—liver cancer	0.000243	0.00241	CcSEcCtD
Ondansetron—Cough—Epirubicin—liver cancer	0.000242	0.00239	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—liver cancer	0.000241	0.00239	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—liver cancer	0.00024	0.00238	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—liver cancer	0.000238	0.00235	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—liver cancer	0.000236	0.00233	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—liver cancer	0.000235	0.00233	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—liver cancer	0.000235	0.00233	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000234	0.00232	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—liver cancer	0.000233	0.00231	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—liver cancer	0.000231	0.00229	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—liver cancer	0.00023	0.00228	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—liver cancer	0.00023	0.00228	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—liver cancer	0.000226	0.00224	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—liver cancer	0.000226	0.00224	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—liver cancer	0.000225	0.00223	CcSEcCtD
Ondansetron—Cough—Doxorubicin—liver cancer	0.000223	0.00221	CcSEcCtD
Ondansetron—Shock—Epirubicin—liver cancer	0.000222	0.0022	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—liver cancer	0.000222	0.0022	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—liver cancer	0.000222	0.00219	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—liver cancer	0.00022	0.00218	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—liver cancer	0.000219	0.00217	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—liver cancer	0.000218	0.00216	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—liver cancer	0.000217	0.00215	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000217	0.00215	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—liver cancer	0.000215	0.00213	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—liver cancer	0.000213	0.00211	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—liver cancer	0.000211	0.00209	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—liver cancer	0.000209	0.00207	CcSEcCtD
Ondansetron—Shock—Doxorubicin—liver cancer	0.000206	0.00204	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—liver cancer	0.000205	0.00203	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—liver cancer	0.000204	0.00202	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—liver cancer	0.000203	0.00201	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—liver cancer	0.000203	0.00201	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—liver cancer	0.000201	0.002	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—liver cancer	0.000201	0.00199	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—liver cancer	0.000195	0.00193	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—liver cancer	0.000195	0.00193	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—liver cancer	0.000195	0.00193	CcSEcCtD
Ondansetron—Constipation—Epirubicin—liver cancer	0.000193	0.00191	CcSEcCtD
Ondansetron—Pain—Epirubicin—liver cancer	0.000193	0.00191	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—liver cancer	0.000188	0.00186	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—liver cancer	0.000186	0.00185	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—liver cancer	0.000186	0.00184	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—liver cancer	0.000186	0.00184	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—liver cancer	0.000185	0.00183	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00018	0.00179	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—liver cancer	0.00018	0.00179	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—liver cancer	0.000179	0.00178	CcSEcCtD
Ondansetron—Pain—Doxorubicin—liver cancer	0.000179	0.00177	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—liver cancer	0.000179	0.00177	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—liver cancer	0.000179	0.00177	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—liver cancer	0.000179	0.00177	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—liver cancer	0.000172	0.00171	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—liver cancer	0.000171	0.00169	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—liver cancer	0.000166	0.00165	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—liver cancer	0.000166	0.00164	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—liver cancer	0.000165	0.00164	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—liver cancer	0.000165	0.00164	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—liver cancer	0.000162	0.00161	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—liver cancer	0.00016	0.00158	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—liver cancer	0.000155	0.00153	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—liver cancer	0.000154	0.00153	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—liver cancer	0.00015	0.00149	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—liver cancer	0.000149	0.00148	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—liver cancer	0.000148	0.00146	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—liver cancer	0.000144	0.00142	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—liver cancer	0.000143	0.00142	CcSEcCtD
Ondansetron—Rash—Epirubicin—liver cancer	0.000142	0.00141	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—liver cancer	0.000142	0.00141	CcSEcCtD
Ondansetron—Headache—Epirubicin—liver cancer	0.000142	0.0014	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—liver cancer	0.000138	0.00137	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—liver cancer	0.000133	0.00132	CcSEcCtD
Ondansetron—Rash—Doxorubicin—liver cancer	0.000132	0.00131	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—liver cancer	0.000132	0.0013	CcSEcCtD
Ondansetron—Headache—Doxorubicin—liver cancer	0.000131	0.0013	CcSEcCtD
Ondansetron—HTR1B—Signaling Pathways—APC—liver cancer	1.27e-05	0.000124	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—H2AFX—liver cancer	1.27e-05	0.000124	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL2—liver cancer	1.27e-05	0.000123	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NR1H4—liver cancer	1.26e-05	0.000123	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL6—liver cancer	1.26e-05	0.000122	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CB—liver cancer	1.25e-05	0.000122	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CRABP1—liver cancer	1.25e-05	0.000122	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTA3—liver cancer	1.24e-05	0.000121	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTP1—liver cancer	1.22e-05	0.000119	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTP1—liver cancer	1.22e-05	0.000119	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KDR—liver cancer	1.22e-05	0.000118	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK14—liver cancer	1.21e-05	0.000118	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HMOX1—liver cancer	1.21e-05	0.000117	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HMOX1—liver cancer	1.2e-05	0.000117	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—BRAF—liver cancer	1.19e-05	0.000116	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ESR1—liver cancer	1.19e-05	0.000115	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—F2—liver cancer	1.17e-05	0.000114	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—liver cancer	1.16e-05	0.000113	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.16e-05	0.000113	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CG—liver cancer	1.15e-05	0.000112	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL2—liver cancer	1.15e-05	0.000112	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PSMA4—liver cancer	1.15e-05	0.000112	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PSMD10—liver cancer	1.15e-05	0.000112	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TERT—liver cancer	1.15e-05	0.000112	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.14e-05	0.000111	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PSMA4—liver cancer	1.14e-05	0.000111	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PSMD10—liver cancer	1.14e-05	0.000111	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTA4—liver cancer	1.14e-05	0.000111	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.13e-05	0.00011	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTM1—liver cancer	1.12e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTM1—liver cancer	1.12e-05	0.000109	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CG—liver cancer	1.12e-05	0.000109	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APC—liver cancer	1.12e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GOT2—liver cancer	1.12e-05	0.000109	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CD—liver cancer	1.12e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—liver cancer	1.11e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GOT2—liver cancer	1.11e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTA2—liver cancer	1.11e-05	0.000108	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—liver cancer	1.11e-05	0.000108	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SERPINE1—liver cancer	1.1e-05	0.000107	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HPGDS—liver cancer	1.09e-05	0.000106	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—liver cancer	1.09e-05	0.000106	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.09e-05	0.000106	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTA1—liver cancer	1.07e-05	0.000104	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP1A1—liver cancer	1.07e-05	0.000104	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP1A1—liver cancer	1.06e-05	0.000103	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NAT2—liver cancer	1.06e-05	0.000103	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—BRAF—liver cancer	1.05e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP2E1—liver cancer	1.05e-05	0.000102	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KDR—liver cancer	1.05e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP2E1—liver cancer	1.04e-05	0.000102	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK14—liver cancer	1.04e-05	0.000101	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ESR1—liver cancer	1.02e-05	9.95e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CD—liver cancer	1.01e-05	9.86e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALDOB—liver cancer	1.01e-05	9.85e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—F2—liver cancer	1.01e-05	9.83e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.01e-05	9.83e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—liver cancer	1e-05	9.77e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—liver cancer	1e-05	9.73e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RAF1—liver cancer	9.97e-06	9.69e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MTHFR—liver cancer	9.94e-06	9.67e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MTHFR—liver cancer	9.92e-06	9.65e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.91e-06	9.64e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CD—liver cancer	9.85e-06	9.58e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYCS—liver cancer	9.85e-06	9.58e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	9.78e-06	9.51e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYCS—liver cancer	9.77e-06	9.5e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—liver cancer	9.76e-06	9.49e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PSMD10—liver cancer	9.75e-06	9.49e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PSMA4—liver cancer	9.75e-06	9.49e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARA—liver cancer	9.75e-06	9.48e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SERPINE1—liver cancer	9.74e-06	9.48e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MTOR—liver cancer	9.73e-06	9.47e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CB—liver cancer	9.73e-06	9.47e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARA—liver cancer	9.73e-06	9.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APC—liver cancer	9.67e-06	9.41e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CG—liver cancer	9.67e-06	9.41e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GOT1—liver cancer	9.67e-06	9.4e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GGT1—liver cancer	9.67e-06	9.4e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CRABP1—liver cancer	9.66e-06	9.4e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—liver cancer	9.65e-06	9.38e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GOT1—liver cancer	9.58e-06	9.32e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GGT1—liver cancer	9.58e-06	9.32e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GOT2—liver cancer	9.49e-06	9.23e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—liver cancer	9.29e-06	9.04e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1B—liver cancer	9.13e-06	8.88e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BRAF—liver cancer	9.09e-06	8.85e-05	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—liver cancer	9.03e-06	8.79e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—liver cancer	8.95e-06	8.71e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—liver cancer	8.94e-06	8.69e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP2E1—liver cancer	8.92e-06	8.68e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—liver cancer	8.89e-06	8.65e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—liver cancer	8.86e-06	8.62e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CB—liver cancer	8.83e-06	8.59e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RAF1—liver cancer	8.8e-06	8.56e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—liver cancer	8.71e-06	8.47e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JUN—liver cancer	8.69e-06	8.46e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—liver cancer	8.68e-06	8.45e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.64e-06	8.4e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—liver cancer	8.63e-06	8.39e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—liver cancer	8.61e-06	8.37e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CB—liver cancer	8.59e-06	8.35e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MTOR—liver cancer	8.59e-06	8.35e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HMOX1—liver cancer	8.56e-06	8.33e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CD—liver cancer	8.5e-06	8.27e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HMOX1—liver cancer	8.49e-06	8.26e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—liver cancer	8.46e-06	8.23e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HPGDS—liver cancer	8.44e-06	8.21e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1A—liver cancer	8.43e-06	8.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—liver cancer	8.42e-06	8.19e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SERPINE1—liver cancer	8.41e-06	8.18e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—liver cancer	8.35e-06	8.12e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYCS—liver cancer	8.35e-06	8.12e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—liver cancer	8.33e-06	8.11e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—liver cancer	8.33e-06	8.1e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK8—liver cancer	8.23e-06	8e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—liver cancer	8.2e-06	7.98e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—liver cancer	8.2e-06	7.98e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GOT1—liver cancer	8.19e-06	7.97e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GGT1—liver cancer	8.19e-06	7.97e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—liver cancer	8.06e-06	7.84e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—liver cancer	8.06e-06	7.84e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—liver cancer	8.04e-06	7.82e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—liver cancer	7.98e-06	7.76e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—liver cancer	7.97e-06	7.75e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—liver cancer	7.91e-06	7.7e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—liver cancer	7.9e-06	7.68e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—liver cancer	7.89e-06	7.67e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—liver cancer	7.85e-06	7.63e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—liver cancer	7.69e-06	7.48e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JUN—liver cancer	7.67e-06	7.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—liver cancer	7.65e-06	7.44e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—liver cancer	7.61e-06	7.41e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—liver cancer	7.59e-06	7.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RAF1—liver cancer	7.59e-06	7.39e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A1—liver cancer	7.56e-06	7.36e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PSMA4—liver cancer	7.53e-06	7.32e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PSMD10—liver cancer	7.53e-06	7.32e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—liver cancer	7.52e-06	7.31e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A1—liver cancer	7.5e-06	7.29e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—liver cancer	7.46e-06	7.26e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1A—liver cancer	7.44e-06	7.23e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CB—liver cancer	7.41e-06	7.21e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MTOR—liver cancer	7.41e-06	7.21e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—liver cancer	7.36e-06	7.16e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CD—liver cancer	7.34e-06	7.14e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CD—liver cancer	7.33e-06	7.13e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GOT2—liver cancer	7.32e-06	7.12e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK8—liver cancer	7.26e-06	7.06e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMOX1—liver cancer	7.25e-06	7.06e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—liver cancer	7.25e-06	7.05e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—liver cancer	7.24e-06	7.04e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—liver cancer	7.23e-06	7.03e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—liver cancer	7.08e-06	6.88e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—liver cancer	7.05e-06	6.86e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—liver cancer	6.99e-06	6.8e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—liver cancer	6.99e-06	6.8e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—liver cancer	6.97e-06	6.78e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—liver cancer	6.96e-06	6.77e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARA—liver cancer	6.92e-06	6.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP2E1—liver cancer	6.88e-06	6.7e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—liver cancer	6.88e-06	6.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARA—liver cancer	6.86e-06	6.67e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—liver cancer	6.82e-06	6.63e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—liver cancer	6.81e-06	6.62e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—liver cancer	6.77e-06	6.59e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—liver cancer	6.76e-06	6.58e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—liver cancer	6.7e-06	6.52e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—liver cancer	6.64e-06	6.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—liver cancer	6.64e-06	6.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUN—liver cancer	6.62e-06	6.44e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—liver cancer	6.57e-06	6.39e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—liver cancer	6.46e-06	6.28e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—liver cancer	6.44e-06	6.27e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYCS—liver cancer	6.44e-06	6.27e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1A—liver cancer	6.42e-06	6.24e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1A1—liver cancer	6.41e-06	6.23e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CB—liver cancer	6.4e-06	6.22e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CB—liver cancer	6.38e-06	6.21e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GGT1—liver cancer	6.32e-06	6.15e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GOT1—liver cancer	6.32e-06	6.15e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK8—liver cancer	6.27e-06	6.1e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—liver cancer	6.25e-06	6.08e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—liver cancer	6.17e-06	6e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.16e-06	5.99e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—liver cancer	6.15e-06	5.98e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—liver cancer	5.97e-06	5.81e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—liver cancer	5.93e-06	5.77e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—liver cancer	5.93e-06	5.76e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—liver cancer	5.87e-06	5.71e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARA—liver cancer	5.86e-06	5.7e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—liver cancer	5.79e-06	5.63e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—liver cancer	5.74e-06	5.58e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—liver cancer	5.73e-06	5.57e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—liver cancer	5.72e-06	5.56e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—liver cancer	5.7e-06	5.54e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—liver cancer	5.68e-06	5.52e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—liver cancer	5.67e-06	5.51e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMOX1—liver cancer	5.6e-06	5.45e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—liver cancer	5.49e-06	5.34e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—liver cancer	5.38e-06	5.24e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—liver cancer	5.32e-06	5.18e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—liver cancer	5.31e-06	5.17e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.26e-06	5.12e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—liver cancer	5.25e-06	5.11e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—liver cancer	5.24e-06	5.09e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—liver cancer	5.22e-06	5.07e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CD—liver cancer	5.21e-06	5.07e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CD—liver cancer	5.16e-06	5.02e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—liver cancer	5.14e-06	5e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—liver cancer	5.1e-06	4.96e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—liver cancer	5.06e-06	4.93e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—liver cancer	5.02e-06	4.88e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A1—liver cancer	4.95e-06	4.81e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—liver cancer	4.92e-06	4.78e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—liver cancer	4.85e-06	4.71e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—liver cancer	4.84e-06	4.71e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—liver cancer	4.84e-06	4.71e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—liver cancer	4.64e-06	4.51e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—liver cancer	4.61e-06	4.49e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CB—liver cancer	4.54e-06	4.42e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARA—liver cancer	4.52e-06	4.4e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—liver cancer	4.52e-06	4.4e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CB—liver cancer	4.5e-06	4.38e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CD—liver cancer	4.41e-06	4.29e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—liver cancer	4.4e-06	4.28e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—liver cancer	4.37e-06	4.25e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—liver cancer	4.36e-06	4.24e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—liver cancer	4.28e-06	4.16e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—liver cancer	4.18e-06	4.07e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—liver cancer	4e-06	3.89e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—liver cancer	3.9e-06	3.79e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—liver cancer	3.89e-06	3.79e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—liver cancer	3.87e-06	3.77e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CB—liver cancer	3.85e-06	3.74e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—liver cancer	3.74e-06	3.64e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—liver cancer	3.69e-06	3.59e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CD—liver cancer	3.41e-06	3.31e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—liver cancer	3.36e-06	3.27e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—liver cancer	3.19e-06	3.1e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—liver cancer	3.18e-06	3.09e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CB—liver cancer	2.97e-06	2.89e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—liver cancer	2.77e-06	2.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—liver cancer	2.74e-06	2.67e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—liver cancer	2.34e-06	2.28e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—liver cancer	2.26e-06	2.2e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—liver cancer	2.24e-06	2.18e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—liver cancer	1.92e-06	1.86e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—liver cancer	1.81e-06	1.76e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—liver cancer	1.48e-06	1.44e-05	CbGpPWpGaD
